Literature DB >> 22716017

Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of pancreatic carcinoma in the peripheral nerve plexus.

Peng Cheng1, Gang Jin, Xiangui Hu, Min Shi, Yijie Zhang, Rui Liu, Yingqi Zhou, Chenghao Shao, Jianming Zheng, Minghua Zhu.   

Abstract

Cancer cells can metastasize throughout the body by various mechanisms, including the lymphatic system, resulting in tumor-induced lymphangiogenesis that can profoundly affect patient survival. The aim of the present study was to examine the role of lymphangiogenesis in the metastasis of pancreatic cancer to the peripheral nerve plexus. Immunohistochemistry was performed to analyze specimens obtained from 70 ductal adenocarcinoma patients. The markers used included lymphangiogenic factor vascular endothelial growth factor (VEGF)-C, the lymphatic-specific marker D2-40, and cytokeratin 19, an independent prognostic factor for pancreatic tumors. The relationship between survival rate and invasion of both the lymphatic vessels and peripancreatic nerve plexus (PNP) was evaluated, with clearly elevated lymphatic vessel density (LVD) in tissues adjacent to the cancer tissues. In fact, LVD levels were higher in adjacent tissues than in localized cancer tissues, and lymphatic vessel invasion into tissues adjacent to the tumor was significantly correlated with both PNP invasion (P = 0.005) and lymph node metastasis (P = 0.010). Correspondingly, LVD in tissues adjacent to the tumor was correlated with both invasion of lymphatic vessels surrounding the tumor (P = 0.024) and VEGF-C expression (P = 0.031); in addition, VEGF-C expression was correlated with invasion of lymphatic vessels around the tumor (P = 0.004). Survival rates were significantly lower in patients in whom there was peritumor lymphatic vessel invasion (P < 0.001), extrapancreatic nerve plexus invasion (P = 0.001), and/or lymph node metastasis (P < 0.001). Based on these results, lymphatic invasion associated with adjacent tumor growth likely contributes to the development of metastatic tumors that invade the PNP.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22716017     DOI: 10.1111/j.1349-7006.2012.02364.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?

Authors:  Matthäus Felsenstein; Flora Lindhammer; Mathilde Feist; Karl Herbert Hillebrandt; Lea Timmermann; Christian Benzing; Brigitta Globke; Dario Zocholl; Mengwen Hu; Uli Fehrenbach; Bruno Valentin Sinn; Uwe Pelzer; Igor Maximillian Sauer; Johann Pratschke; Thomas Malinka
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

3.  Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.

Authors:  Jesse Gore; Imade E Imasuen-Williams; Abass M Conteh; Kelly E Craven; Monica Cheng; Murray Korc
Journal:  Cancer Lett       Date:  2016-06-03       Impact factor: 8.679

4.  Survival in resectable pancreatic ductal adenocarcinoma with para-aortic lymph node dissection: A retrospective study in Vietnamese population.

Authors:  Lan Thi Nguyen; Hung Van Nguyen; Dang Hai Do; Khiem Thanh Nguyen; Anh Tuan Do; Ha Hoang Pham; Chinh Duc Nguyen
Journal:  Ann Med Surg (Lond)       Date:  2021-05-01

5.  Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.

Authors:  Hsiu-Mei Chen; Chia-Hua Tsai; Wen-Chun Hung
Journal:  Oncotarget       Date:  2015-06-20

6.  Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma.

Authors:  Toshimitsu Iwasaki; Nobuyoshi Hiraoka; Yoshinori Ino; Kosei Nakajima; Yoji Kishi; Satoshi Nara; Minoru Esaki; Kazuaki Shimada; Hitoshi Katai
Journal:  Cancer Sci       Date:  2019-03-19       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.